Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

Stock Information for Akari Therapeutics Plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Akari Therapeutics Plc

Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Corbus Pharmaceuticals Announces Pricing of Public Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.